%0 Journal Article %A Ikeda, Satoshi %A Kato, Terufumi %A Ogura, Takashi %A Sekine, Akimasa %A Oda, Tsuneyuki %A Masuda, Noriyuki %A Igawa, Satoshi %A Katono, Ken %A Otani, Sakiko %A Yamada, Kouzo %A Saito, Haruhiro %A Kondo, Tetsuro %A Hosomi, Yukio %A Nakahara, Yoshiro %A Nishikawa, Masanori %A Utumi, Keiko %A Misumi, Yuki %A Yamanaka, Takeharu %A Sakamaki, Kentaro %A Okamoto, Hiroaki %D 2018 %T Additional file 2: of Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016 %U https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_of_Phase_II_study_of_bevacizumab_cisplatin_and_docetaxel_plus_maintenance_bevacizumab_as_first-line_treatment_for_patients_with_advanced_non-squamous_non-small-cell_lung_cancer_combined_with_exploratory_analysis_of_circulating_endothelia/5946055 %R 10.6084/m9.figshare.5946055.v1 %2 https://springernature.figshare.com/ndownloader/files/10639195 %K Non-small cell lung cancer %K Docetaxel %K Bevacizumab %K Circulating endothelial cell %X Table S1. CEC data and treatment efficacy of 35 patients whose CEC count was measured on days 1 and 8. Abbreviations: EGFR, epidermal growth factor receptor; CEC, circulating endothelial cell; PR, partial response; SD, stable disease; PFS, progression-free survival; OS, overall survival. (DOCX 22 kb) %I figshare